Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
World game at war: why some European nations have threatened a World Cup boycott 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
SAINT LAURENT, Quebec, May 03, 2018 -- IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) today announced that it will release its first quarter 2018 financial results after market close on May 10, 2018.
An accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer, and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:
Date: Thursday, May 10, 2018
Time: 4:30 p.m. ET
Conference dial-in: (833) 231-8269
International dial-in: (647) 689-4114
Conference ID: 2398086
Webcast Registration: Click here
Following the live call, a replay will be available on the Company's website, www.intelgenx.com, under "Investor Relations".
About IntelGenx:
Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.
IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.
Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.
For more information, please contact: Stephen Kilmer Investor Relations (514) 331-7440 ext 232 [email protected] Or Andre Godin, CPA, CA Executive Vice-President and CFO IntelGenx Corp. (514) 331-7440 ext 203 [email protected]
